Related Experiment Videos
Saperconazole therapy in a rabbit model of invasive aspergillosis
T F Patterson1, D George, P Miniter
1Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06510.
Abstract:
The efficacy of orally and intravenously administered saperconazole against Aspergillus fumigatus was assessed in an immunosuppressed temporarily leukopenic rabbit model of invasive aspergillosis and compared with that of amphotericin B. Oral saperconazole at dosages of 5, 10, and 15 mg/kg of body weight per day improved survival compared with that of controls. In addition, saperconazole at 10 and 15 mg/kg/day reduced the tissue burden and reduced levels of circulating antigen, which correlated with increasing dosages of saperconazole. Intravenous saperconazole produced levels in serum more than 10-fold that of oral therapy. Intravenous saperconazole not only improved survival and reduced antigen levels but also significantly eradicated A. fumigatus from tissues compared with those of controls and was as effective as amphotericin B in these studies. Saperconazole was effective in the treatment of experimental invasive aspergillosis and demonstrates the potential of the newer azoles in therapy for invasive aspergillosis.
Insights
Saperconazole effectively treated invasive aspergillosis in rabbits. Both oral and intravenous administration improved survival and reduced fungal burden, with intravenous therapy showing comparable efficacy to amphotericin B.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Invasive aspergillosis, caused by Aspergillus fumigatus, is a serious opportunistic infection.
- Limited treatment options and emerging resistance necessitate novel antifungal agents.
Purpose of the Study:
- To evaluate the efficacy of saperconazole against Aspergillus fumigatus in an experimental invasive aspergillosis model.
- To compare the efficacy of oral and intravenous saperconazole with amphotericin B.
Main Methods:
- An immunosuppressed, temporarily leukopenic rabbit model of invasive aspergillosis was utilized.
- Animals were treated with varying dosages of oral or intravenous saperconazole or amphotericin B.
- Survival rates, tissue fungal burden, and circulating antigen levels were assessed.
Main Results:
- Oral saperconazole improved survival and reduced fungal burden and antigen levels in a dose-dependent manner.
- Intravenous saperconazole achieved higher serum concentrations and demonstrated significant eradication of A. fumigatus from tissues.
- Intravenous saperconazole was as effective as amphotericin B in improving survival and reducing fungal burden.
Conclusions:
- Saperconazole demonstrates significant efficacy in treating experimental invasive aspergillosis.
- Both oral and intravenous routes are effective, with intravenous administration showing superior results.
- Saperconazole represents a promising therapeutic candidate among newer azole antifungals for invasive aspergillosis.